Kantonsspital St.Gallen
login

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

U Nitz, O Gluz, Jens Huober, H H Kreipe, R E Kates, A Hartmann, R Erber, Z Moustafa, M Scholz, B Lisboa, S Mohrmann, V Möbus, D Augustin, G Hoffmann, E Weiss, S Böhmer, R Kreienberg, A Du Bois, D Sattler, C Thomssen, M Kiechle, F Jänicke, D Wallwiener, N Harbeck & W Kuhn

citation Nitz U, Gluz O, Huober J, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
   
type journal paper/review (English)
date of publishing 2017
journal title Ann Oncol (28/11)
ISSN electronic 1569-8041
pages 2899
PubMed 27634692
DOI 10.1093/annonc/mdw349